ER
Emergent BioSolutions Inc. (ER4)
FSX
6.04
-0.16 (-2.58%)
Closed
Oct 9, 2026
Day's Range
6.046.04
52 wk Range
3.8111.72
Financial Statements - ER4 - Emergent BioSolutions Inc.
Revenue
705.20M▼ 30.4%
Net Income
52.60M▲ 127.6%Net Margin 7.5%
EBITDA
262.30M▲ 559.0%
Free Cash Flow
156.80M▲ 338.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 705.20M | 1.01B | 1.02B | 1.07B | 1.63B | 1.46B |
| Cost of Goods | 326.20M | 681.30M | 705.40M | 693.10M | 748.10M | 537M |
| Gross Profit | 379M | 332.30M | 317.60M | 383M | 891.30M | 925.20M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 112.30M | -81.50M | -201.50M | -163.30M | 383.10M | 438.50M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 29.80M | 9.60M | -441.80M | -18.40M | -45.40M | 4.70M |
| Pre Tax Income | 82.80M | -142.90M | -731.20M | -219M | 303.20M | 411.90M |
| Income Tax | 30.20M | 47.70M | 29.30M | -7.40M | 83.70M | 106.10M |
| Net Income | 52.60M | -190.60M | -760.50M | -211.60M | 219.50M | 305.80M |
| EPS Basic | 0.98 | -3.6 | -14.85 | -4.47 | 4.32 | 5.79 |
| EPS Diluted | 0.93 | -3.6 | -14.85 | -4.47 | 4.27 | 5.67 |
| Basic Shares Outstanding | 53.50M | 53M | 53.68M | 51.44M | 54.93M | 54.11M |
| Diluted Shares Outstanding | 53.50M | 53M | 53.68M | 51.44M | 54.93M | 54.11M |
| Ebit | 142.10M | -71.90M | -643.30M | -181.70M | 337.70M | 443.20M |
| Ebitda | 262.30M | 39.80M | -67.50M | -31.70M | 503.20M | 557.70M |
| Net Income Continuous Operations | 52.60M | -190.60M | -760.50M | -211.60M | 219.50M | 305.80M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
